The June public meeting was dedicated to presentations from federal and non-federal stakeholders surrounding topic areas related to incentives for the development of vaccines, diagnostics, and therapeutics. The topic of the environment and its intersection with antibiotic-resistance was also discussed.
Agenda
Webcast Information
Meeting Documents
March 2016 - Letter to the PACCARB Chair and Vice Chair
Presentations
Incentives and USG Experience
Incentives – International Experience
Incentives – Industry Experience
Plasmid-Mediated Colistin Resistance – U.S. Government Findings and Response
Antibiotic Resistance in the Healthcare Environment
FDA’s Guidance for Industry #213
Drivers of AMR and Antibiotic Metabolites in the Environment
Environmental Compartments of AMR and Antibiotic Metabolites
Environmental AMR Surveillance and USG Activities
